Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).
Clinical trial NCT04068181 · COMPLETED
Trial details
- NCT number
- NCT04068181
- Sponsor
- Amgen
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-01-22
- Primary completion
- 2021-08-19
- Enrollment
- 72
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.